3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Accelerated Phase
3
Leukemia
3
Graft vs Host Disease
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Congenital Abnormalities
2
Anemia, Refractory, with Excess of Blasts
2
Anemia, Refractory
2
Thymic aplasia
1
Skin Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Immunologic Deficiency Syndromes
1
Hodgkin Disease
1
Healthy
1
Burkitt Lymphoma
1
Interventions
Drug Delivery Systems
1
Cyclosporine
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pulmonary Disease, Chronic Obstructive
×
Cyclosporine
×
Clear all
NCT06892756
2025-09-09
DDI2
Chiesi Farmaceutici S.p.A.
Phase 1
Completed
30 enrolled